Home > Neurology > EAN 2020 > Multiple Sclerosis > Serum NfL predicts long-term clinical outcomes in MS

Serum NfL predicts long-term clinical outcomes in MS

Higher serum levels of neurofilament light chain (NfL) close to the time of multiple sclerosis (MS) onset are a sensitive marker of subsequent relatively poor clinical outcomes, results of a prospective cohort study with over 15 years of follow-up suggest [1]. The authors claim that these patients may benefit from a more aggressive initial treatment.

A correlation between MS disease activity and elevated NfL is already well established. Researchers from the Ottawa Hospital Research Institute (Canada) evaluated the prognostic value of serum NfL levels obtained shortly after MS diagnosis to identify patients likely to have a more aggressive disease course. Frozen and stored samples from MS patients were provided by the Ottawa MS biobank. A total of 67 patients were identified whose serum had been collected within 5 years of first MS symptom onset.

The team investigated the serum samples obtained from the biobank (baseline) and over 15 years of routine...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on